NewBridge Pharmaceuticals is a regional specialty company established to bridge the access gap and partner with pharma & biotech companies to in-license and commercialize FDA or EMA/European approved innovative pharmaceutics, biologics, & other healthcare solutions in the Middle East and Africa region. The areas of Oncology, Immunology, Neuroscience, Gastrointestinal & Nutrition are NewBridge’s current strategic focus. The existing product portfolio was built to address unmet medical needs in the region & enabled the company not just to gain substantial presence, but also to help patients gain access to these much-needed innovations. NewBridge is driven by highly experienced leadership in the biopharmaceutical industry regionally & globally, as well as talented motivated teams with a proven track record of regional achievements, which collectively has allowed NewBridge to establish itself as a strategic & successful pharmaceutical partner of choice in the MENA Region. NewBridge offers flexible partnership opportunities & best practices in the areas of commercial, regulatory, and medical affairs striving for quality performance & high standards of compliance that pharmaceutical companies look for in a partner to serve as an extension of their practices & values in local markets. NewBridge is well backed by strong institutional & corporate investors who provide us with the extensive life science network & diverse investment expertise needed to achieve our vision & build a platform of successful alliances in the region, and create value in an innovative business approach. This integrated strategy of regional expertise & strong global business network position NewBridge uniquely as an institutional one-stop-solution for our partners in its offering & as a preferred partner-of-choice for the biopharmaceutical & other healthcare companies seeking multi-country access in Middle East and Africa with its growing economies, yet complex regulations & access hurdles.
